Objective: The objective of this study was to investigate adherence to practice guidelines for antiplatelet and statin use after postoperative myocardial infarction (POMI) and its effect on late mortality following vascular surgery in a multicenter registry.
Cardiovascular complications are a leading cause of morbidity and mortality in patients undergoing vascular surgery. Postoperative myocardial infarction (POMI) and troponin elevations greatly increase the rate of subsequent cardiac events and are associated with reduced long-term survival. [1] [2] [3] [4] [5] [6] In a Vascular Study Group of New England study, Simons et al 6 found that POMI was associated with decreased 5-year survival following elective vascular surgery. De Martino et al 7 reported that antiplatelet and statin therapy in the perioperative period was associated with improved 30-day mortality and improved 5-year survival. The use of antiplatelet agents and statins in vascular surgery patients experiencing POMI has not been previously reported. Current American College of Cardiology/ American Heart Association guidelines include single antiplatelet therapy (SAPT) and statin therapy after POMI based on level 1A evidence. [8] [9] [10] A recent large randomized trial reported no difference in late cardiovascular events between clopidogrel and ticagrelor for patients with symptomatic peripheral arterial disease (PAD). 11 However, the benefit of SAPT vs dual antiplatelet therapy (DAPT) and statin therapy in patients who suffer POMI after vascular surgery remains undecided, with current recommendations for DAPT in those patients treated with percutaneous coronary intervention. The primary aim of this study was to assess adherence to practice guidelines for treatment of patients with POMI following vascular surgery with discharge cardiac medications (CMs), defined as (1) SAPT (aspirin or P2Y 12 inhibitor) or DAPT (aspirin and P2Y 12 inhibitor) and (2) statin therapy. We then compared survival of patients after surgery among CM groups. Secondary aims were to evaluate regional differences in CM use.
METHODS
Vascular Quality Initiative (VQI) database. The VQI is a national vascular surgery quality improvement initiative composed of 18 regional quality improvement groups representing >350 community and academic hospitals in the United States and Canada. 12 Entry of consecutive procedures by each participating center is ensured by annual audit against hospital claims data submitted by each center. 13 Further details about the VQI and the Society for Vascular Surgery Patient Safety Organization are available online at http://www. vascularqualityinitiative.org/.
Patients. This is a retrospective cohort study of 2042 procedures with POMI between 2005 and 2015. To avoid possible spurious results, 232 procedures were excluded because of troponin elevation in patients with renal insufficiency or on dialysis or for troponin elevations associated with thoracic aortic disease, such as dissection, penetrating ulcer, or trauma. In addition, 61 patients who underwent thoracic endovascular aortic repair were excluded. The remaining 1749 vascular surgery procedures constituted the study cohort, including carotid endarterectomy (CEA; n ¼ 384), endovascular aneurysm repair (EVAR; n ¼ 270), infrainguinal bypass (INFRA; n ¼ 555), open abdominal aortic aneurysm (OAAA) repair (n ¼ 314), and suprainguinal bypass (SUPRA; n ¼ 226). Patients with a prior procedure (n ¼ 55 [3%]) in the VQI database were included. Because we aimed to examine the effect of discharge CM on survival, we excluded patients who died in the hospital postoperatively (n ¼ 215 [12%]) from the survival analysis. The remaining 1534 procedures were included for the survival analysis.
Covariates. More than 150 patient demographic, history, intraoperative, and postoperative variables are prospectively collected for each procedure in the VQI registry. 14 ) were considered as not taking these medications. Data on medications were complete, with <1% missing preoperatively and none at discharge. Aspirin or statin dosage was not recorded. Prescription fills or adherence to CM was not measured after discharge. Mortality recorded in the VQI registry was cross-referenced to the Social Security Death Index.
Regional variation in CM use. Regional variation across 18 VQI groups was assessed after excluding patients not in a regional group (n ¼ 265) and regions with fewer than five POMIs per procedure (n ¼ 47). Regional variation was analyzed according to procedure type because of variation in center and regional participation in the six registries and differing rates of POMI for each operation.
Statistical analysis. Univariate analyses were conducted with t-tests for continuous variables and c compare CM regimens at discharge across five groups: (1) none, (2) antiplatelet only, (3) statin only, (4) SAPT and statin, and (5) DAPT and statin. CM regimen was also analyzed as a dichotomous variable, with groups 1 to 3 compared with groups 4 and 5. Patients with in-hospital mortality were excluded from the long-term survival analysis to test the association of discharge medications on survival. A multivariable proportional hazards model was performed for factors associated with mortality. Covariates with P < .20, including preoperative and postoperative medications, were entered into the model, followed by stepwise backward selection until only significant variables with P < .05 remained.
Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and Stata 13 (StataCorp, College Station, Tex). This study follows the principles outlined in the Declaration of Helsinki. The University of Vermont Institutional Review Board has approved the use of deidentified data from the VQI for research purposes and does not require written informed consent.
RESULTS
The demographic characteristics and comorbidities were typical for patients undergoing vascular operations (Table I) , including INFRA (32%), CEA (22%), OAAA (18%), EVAR (15%), and SUPRA (13%). Patients had a mean age of 72 years, with the majority male (65%) and of white race (89%). Comorbidities included coronary artery disease (44%), congestive heart failure (21%), chronic obstructive pulmonary disease (COPD; 32%), diabetes (40%), and renal insufficiency (7%). The majority of patients were taking a statin (74%) or SAPT agent (56%) before surgery, with fewer receiving DAPT (22% ;  Table II ). Combined antiplatelet and statin therapy was used in 63% (SAPT þ statin, 43%; DAPT þ statin, 20%) of cases before surgery. Beta blockers were used in 71% of procedures preoperatively.
At discharge, 23% of patients with POMI were not taking a statin. After discounting of the 5% intolerant of the medication, 18% of patients eligible for therapy were not discharged on a statin. Antiplatelet prescription at discharge was 84%, representing a 6% increase from the preoperative rate. Combined antiplatelet and statin was used in 74% of patients at discharge (SAPT þ statin, 42%; DAPT þ statin, 32%), representing a 9% increase from admission. The method of POMI diagnosis was based on clinical or ECG criteria in 52% and troponin elevation alone in 48% (P ¼ .23).
Antiplatelet and statin use and survival after POMI. Survival analysis showed significant differences between groups (log-rank, P ¼ .005; Fig 1) . These results did not change when in-hospital deaths were included in the analysis (log-rank, P < .001). After analysis of all pairwise comparisons between groups, several statistically significant differences were noted. DAPT plus statin therapy was associated with improved survival compared with antiplatelet alone (P ¼ .002) and neither antiplatelet nor statin group (P ¼ .003). There was no difference in survival between the DAPT and statin group and statin without antiplatelet group (P ¼ .28). SAPT plus statin therapy was associated with improved survival compared with antiplatelet alone (P ¼ .03) and neither antiplatelet nor statin group (P ¼ .02). There was no significant difference in survival between the SAPT and statin group and the statin without antiplatelet group (P ¼ .49). No difference was noted between SAPT and statin vs DAPT and statin (P ¼ .19). We further analyzed the effect of combined medications by comparing dichotomous groups: SAPT or DAPT plus statin vs antiplatelet alone, statin alone, or neither medication. Discharge on SAPT or DAPT and statin therapy was associated with improved survival compared with those receiving noncombination or no therapy (log-rank, P ¼ .001), with mortality rates of 21% and 31%, respectively, with mean follow-up of 5.5 and 4.9 years, respectively (Fig 2) . 12 antagonist, statins, and beta blockers (HR, 0.73; 95% CI, 0.55-0.97; P ¼ .03). The interaction term for discharge medication use and procedure was not significant (P ¼ .69), indicating that the improved survival for those receiving combined statin and antiplatelet therapy did not differ significantly by procedure.
Regional variation. Regional variation in CM at discharge following POMI was also observed with a range of 33% to 100% (P ¼ .05) overall (Fig 3) . Regional variation was noted within each procedure (CEA, 56%-91%; EVAR, 56%-88%; INFRA, 57%-100%; OAAA, 33%-80%; and SUPRA, 53%-100%).
DISCUSSION
Research on medical optimization before noncardiac surgery with perioperative cardiovascular medications has been extensively reported, leading to several consensus specialty documents. [8] [9] [10] 15 Numerous studies have examined the benefits of antiplatelet agents and statins before surgery with the consensus that postoperative cardiac events are reduced and long-term survival is increased for patients receiving combination therapy. Fewer studies report on differences across surgical specialties with focus on POMI. 16 VQI data have shown an 18% improvement in 5-year survival for patients receiving combined antiplatelet and statin therapy preoperatively and at discharge. 7 We focused on a specific subset of vascular surgery patients with POMI, suspecting that CM at discharge would more closely match current guidelines in these at-risk patients. The use of an antiplatelet agent and statin is supported by level 1A evidence in this population of patients. Surprisingly, 16% were not discharged on an antiplatelet agent, 23% were not taking a statin, and 26% were not taking a combination of these medications even after suffering a cardiac event. When patients intolerant of these medications were discounted, 18% of those eligible for statin treatment and 12% eligible for antiplatelet agent were not discharged on these medications. This contrasts sharply with the cardiology literature on acute myocardial infarction, in which statin prescribing rates meet or exceed 90% in patients hospitalized with acute myocardial infarction. 17, 18 It is possible that combined medications were not used for patients with troponin elevations because of the misconception that these events are less clinically significant. When the subset not discharged on combined medications was examined, we found that POMI diagnosis was based on clinical or ECG criteria in 52% and troponin elevation alone in 48% (P ¼ .23), suggesting that type of cardiac event was not a factor. We demonstrated an improvement in late survival after POMI in patients discharged on an antiplatelet agent and statin. The mortality rate was reduced from 31% to 21% for patients receiving either SAPT or DAPT and a statin. Whereas a prior meta-analysis called the benefit of antiplatelet therapy into question, finding no significant reduction in overall cardiovascular events in patients with PAD, this study did involve the specific high-risk subset of patients with a postoperative coronary event.
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The best single antiplatelet agent for PAD is unclear and not the focus of this analysis. In 1996, the Clopidogrel vs Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial showed a statistically significant survival benefit for PAD patients taking clopidogrel over aspirin, but the absolute risk reduction in composite events, including vascular death, was small at 0.5%/y. 20 Whereas some studies suggested benefit of specific P2Y 12 inhibitors, the recent Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial showed no difference between clopidogrel and ticagrelor in patients with symptomatic PAD. 11, 21, 22 We were unable to perform subset analysis of P2Y 12 inhibitors because we had only a few patients taking these agents and lacked sufficient power. The benefit of DAPT over SAPT therapy after myocardial infarction remains debatable. In this study of POMI, we did not find a difference in survival between single and dual antiplatelet and statin therapy. This difference was not significant compared with the statin only or statin and antiplatelet group, suggesting that statin therapy may be relatively more important in this population of patients.
Regional variation in combined discharge CM was noted across all procedures with a wide range of 14% to 100%. These data represent an opportunity for action on the part of VQI regions to increase combined CM use in this at-risk group. The authors recommend a target of 100% for antiplatelet and statin at discharge in eligible patients, with exceptions for patients with documented intolerance. Antiplatelet use for acute myocardial infarction is already part of the Merit-based Incentive Payment System. 23, 24 A French registry study reported 88% statin use for patients with acute myocardial infarction.
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There are limitations to this study. Data on preoperative and discharge medications represent only two points in time and do not take into account long-term medication prescriptions and adherence of the patient. Despite this, we believe that discharge after vascular surgery presents an opportunity to administer best medical care and to engage the patients in their vascular health. Maintenance of medication for secondary prevention is a separate issue, with estimates of onethird of patients stopping some CMs after acute myocardial infarction. 26 An emerging body of literature has suggested that outcomes are improved with highdose statins. 16 We did not have data on specific statin medications, dosage levels, timing of postoperative administration, or cholesterol levels. Because there is evidence that earlier administration of statin is important, we recommend preoperative treatment or immediate administration in the event of myocardial infarction. 27, 28 Future VQI projects may include postoperative troponin surveillance, which has been demonstrated to improve medical management, or addition of high-dose statins in patients at higher risk. 29 Finally, we did not examine other important factors, such as coronary intervention for POMI, and medical treatment, such as control of diabetes and smoking cessation, as they were beyond the scope of our study.
CONCLUSIONS
Within the VQI, regional and procedure-specific variation exists in CM regimen after POMI following vascular surgery. Absence of combined antiplatelet and statin therapy at discharge after POMI was associated with 
